Q3 EPS Forecast for Enanta Pharmaceuticals Raised by Analyst

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at Leerink Partnrs increased their Q3 2025 earnings estimates for Enanta Pharmaceuticals in a research note issued on Monday, May 12th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of ($1.28) for the quarter, up from their previous estimate of ($1.42). The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.65) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals’ Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($1.85) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at ($1.18) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million for the quarter, compared to analysts’ expectations of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%.

Other research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 19th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Stock Performance

Shares of Enanta Pharmaceuticals stock opened at $5.75 on Thursday. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $17.24. The company’s 50 day moving average price is $5.50 and its 200-day moving average price is $6.65. The stock has a market capitalization of $122.66 million, a price-to-earnings ratio of -1.16 and a beta of 0.81.

Institutional Trading of Enanta Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ENTA. Barclays PLC boosted its holdings in Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 20,478 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Enanta Pharmaceuticals by 53.7% in the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after acquiring an additional 85,082 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Enanta Pharmaceuticals by 34.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock valued at $1,109,000 after acquiring an additional 49,050 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $26,000. Finally, AlphaQuest LLC boosted its holdings in Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 3,137 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.